Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform

Mario Amendola, Laura Passerini, Ferdinando Pucci, Bernhard Gentner, Rosa Bacchetta, Luigi Naldini

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).

Original languageEnglish (US)
Pages (from-to)1039-1052
Number of pages14
JournalMolecular Therapy
Volume17
Issue number6
DOIs
StatePublished - Mar 18 2009
Externally publishedYes

Fingerprint

MicroRNAs
Small Interfering RNA
Inverted Repeat Sequences
Genes
Forkhead Transcription Factors
Regulatory T-Lymphocytes
RNA Interference
Phenotype

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. / Amendola, Mario; Passerini, Laura; Pucci, Ferdinando; Gentner, Bernhard; Bacchetta, Rosa; Naldini, Luigi.

In: Molecular Therapy, Vol. 17, No. 6, 18.03.2009, p. 1039-1052.

Research output: Contribution to journalArticle

Amendola, M, Passerini, L, Pucci, F, Gentner, B, Bacchetta, R & Naldini, L 2009, 'Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform', Molecular Therapy, vol. 17, no. 6, pp. 1039-1052. https://doi.org/10.1038/mt.2009.48
Amendola, Mario ; Passerini, Laura ; Pucci, Ferdinando ; Gentner, Bernhard ; Bacchetta, Rosa ; Naldini, Luigi. / Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. In: Molecular Therapy. 2009 ; Vol. 17, No. 6. pp. 1039-1052.
@article{da116a086ba24bbdb90cf5d2802438d0,
title = "Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform",
abstract = "RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).",
author = "Mario Amendola and Laura Passerini and Ferdinando Pucci and Bernhard Gentner and Rosa Bacchetta and Luigi Naldini",
year = "2009",
month = "3",
day = "18",
doi = "10.1038/mt.2009.48",
language = "English (US)",
volume = "17",
pages = "1039--1052",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform

AU - Amendola, Mario

AU - Passerini, Laura

AU - Pucci, Ferdinando

AU - Gentner, Bernhard

AU - Bacchetta, Rosa

AU - Naldini, Luigi

PY - 2009/3/18

Y1 - 2009/3/18

N2 - RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).

AB - RNA interference (RNAi) has tremendous potential for investigating gene function and developing new therapies. However, the design and validation of proficient vehicles for stable and safe microRNA (miR) and small interfering RNA (siRNA) delivery into relevant target cells remains an active area of investigation. Here, we developed a lentiviral platform to efficiently coexpress one or more natural/artificial miR together with a gene of interest from constitutive or regulated polymerase-II (Pol-II) promoters. By swapping the stem-loop (sl) sequence of a selected primary transcript (pri-miR) with that of other miR or replacing the stem with an siRNA of choice, we consistently obtained robust expression of the chimeric/artificial miR in several cell types. We validated our platform transducing a panel of engineered cells stably expressing sensitive reporters for miR activity and on a natural target. This approach allowed us to quantitatively assess at steady state the target suppression activity and expression level of each delivered miR and to compare it to those of endogenous miR. Exogenous/artificial miR reached the concentration and activity typical of highly expressed natural miR without perturbing endogenous miR maturation or regulation. Finally, we demonstrate the robust performance of the platform reversing the anergic/suppressive phenotype of human primary regulatory T cells (Treg) by knocking-down their master gene Forkhead Transcription Factor P3 (FOXP3).

UR - http://www.scopus.com/inward/record.url?scp=67349250445&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349250445&partnerID=8YFLogxK

U2 - 10.1038/mt.2009.48

DO - 10.1038/mt.2009.48

M3 - Article

C2 - 19293777

AN - SCOPUS:67349250445

VL - 17

SP - 1039

EP - 1052

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -